I2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies.
i2o Therapeutics has raised $46.0M in total funding. The most recent round was Series A. The last funding was announced in August 2023.
i2o Therapeutics's investors include Touchdown Ventures, JDRF T1D Fund, Sanofi Ventures, Viva BioInnovator.
i2o Therapeutics is headquartered in Allston, United States.
I2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies.
i2o Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"i2o Therapeutics — Funding & Investors." VCBacked, August 28, 2023, https://www.vcbacked.co/company/i2o-therapeutics. Accessed August 1, 2026.
VCBacked. (2023). i2o Therapeutics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/i2o-therapeutics
{{cite web |title=i2o Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/i2o-therapeutics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated